Immunovant, Inc. (IMVT)
| Market Cap | 4.36B |
| Revenue (ttm) | n/a |
| Net Income (ttm) | -79.34M |
| Shares Out | 84.35M |
| EPS (ttm) | -1.29 |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Dividend Yield | n/a |
| Trading Day | January 15 |
| Last Price | $44.02 |
| Previous Close | $44.51 |
| Change ($) | -0.49 |
| Change (%) | -1.10% |
| Day's Open | 44.02 |
| Day's Range | 42.47 - 44.48 |
| Day's Volume | 94,101 |
| 52-Week Range | 8.36 - 52.71 |
Immunovant, Inc. is a clinical-stage biopharmaceutical company focused on monoclonal antibody therapeutic development for autoimmune diseases. Immunovant has a one product pipeline (IMVT-1401)...
NEW YORK, Jan. 12, 2021 (GLOBE NEWSWIRE) -- Immunovant (Nasdaq: IMVT), a clinical-stage biopharmaceutical company focused on enabling normal lives for patients with autoimmune diseases, today ...
There has been plenty of completed SPAC merger news in 2020 as more companies use it to go public and we're looking at the top performers. The post Completed SPAC Mergers 2020: 10 Top Performi...
Company Ended the Quarter With Cash of Approximately $444 Million Company Ended the Quarter With Cash of Approximately $444 Million
NEW YORK, Oct. 20, 2020 /PRNewswire/ -- Purcell Julie & Lefkowitz LLP, a class action law firm dedicated to representing shareholders nationwide, is investigating a potential breach of fiducia...
In October, ther may be price pullbacks in shares of SPAC IPOs, offering long-term investors better entry points. The post 7 of the Most Interesting New SPACs to Take a Chance On appeared firs...
NEW YORK, Sept. 04, 2020 (GLOBE NEWSWIRE) -- Immunovant, Inc. (Nasdaq: IMVT), a clinical-stage biopharmaceutical company focused on enabling normal lives for patients with autoimmune disease...
Hot biotech stock Immunovant on Wednesday priced its secondary offering of 5.27 million shares at $33 per share, as IMVT stock trades near record highs after a rival attracted a big suitor. Th...
NEW YORK, Sept. 02, 2020 (GLOBE NEWSWIRE) -- Immunovant, Inc. (Nasdaq: IMVT) today announced the pricing of its underwritten public offering of 5,270,093 shares of its common stock at a pric...
Immunovant's (IMVT) myasthenia gravis candidate, IMVT-1401, meets endpoints in a mid-stage study.
SAN DIEGO--(BUSINESS WIRE)--Ligand Pharmaceuticals Incorporated (NASDAQ: LGND) OmniAb® partner Immunovant, Inc. (NASDAQ: IMVT) announced positive topline results from ASCEND MG, a Phase 2a stu...
Company to Host Conference Call on August 25, 2020 at 8:30am EDT Company to Host Conference Call on August 25, 2020 at 8:30am EDT
Dr. Elliott previously served as Vice President of Immunology Scientific Innovation at J&J and has led the clinical development of multiple blockbuster immunology products Dr. Elliott previous...
Immunovant Inc (NASDAQ: IMVT) shares were ripping higher Wednesday in a sympathy move.
NEW YORK, Aug. 12, 2020 (GLOBE NEWSWIRE) -- Immunovant, Inc. (Nasdaq: IMVT), a clinical-stage biopharmaceutical company focused on enabling normal lives for patients with autoimmune diseases...
Forget traditional IPOs! This blank check vehicle is proving to be an effective tool for biotech companies to raise capital.
NEW YORK, June 29, 2020 (GLOBE NEWSWIRE) -- Immunovant, Inc. (Nasdaq: IMVT), a clinical-stage biopharmaceutical company focused on enabling normal lives for patients with autoimmune diseases...
Immunovant (IMVT) has seen solid earnings estimate revision activity over the past month, and belongs to a strong industry as well.
As of late, it has definitely been a great time to be an investor of Immunovant
NEW YORK, May 14, 2020 (GLOBE NEWSWIRE) -- Immunovant, Inc. (Nasdaq: IMVT), a clinical-stage biopharmaceutical company focused on enabling normal lives for patients with autoimmune diseases,...
NEW YORK, April 16, 2020 (GLOBE NEWSWIRE) -- Immunovant, Inc. (Nasdaq: IMVT), a clinical-stage biopharmaceutical company focused on enabling normal lives for patients with autoimmune disease...
Immunovant (IMVT) saw a big move last session, as its shares jumped more than 5% on the day, amid huge volumes.
About IMVT
Immunovant, a clinical-stage biopharmaceutical company, develops monoclonal antibodies for the treatment of autoimmune diseases. It develops IMVT-1401, a novel fully human monoclonal antibody that selectively binds to and inhibits the neonatal fragment crystallizable receptor, which is in Phase IIa clinical trials for the treatment of myasthenia gravis and thyroid eye disease, as well as has completed initiation of Phase II clinical trials for the treatment of warm autoimmune hemolytic anemia. The company is headquartered in New York, New York.... [Read more...]
| Industry Biotechnology | |
| CEO Dr. Peter Salzmann M.B.A., M.D. | Employees 42 |
| Stock Exchange NASDAQ | Ticker Symbol IMVT |
Analyst Forecasts
According to 11 analysts, the average rating for Immunovant stock is "Strong Buy." The 12-month stock price forecast is 58.27, which is an increase of 32.37% from the latest price.